PT-141 (Bremelanotide) Dosage Chart
PT-141 (bremelanotide) is a melanocortin receptor agonist (primarily MC4R) studied for hypoactive sexual desire disorder. The FDA-approved formulation, Vyleesi, is a 1.75mg subcutaneous autoinjector dosed on demand, supported by the RECONNECT trials (Kingsberg, Clayton et al., Obstetrics & Gynecology 2019, PMID 31033583).
Half-life
~2.7 hours
Format
Injectable
Purity
≥98%
Protocols
4 variants
Research Protocols
Dosage Protocols
Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.
Protocol 1
Standard FDA-Label Protocol
Dose
1.75mg subcutaneous, 45 minutes before activity
Duration
On-demand, max 8 doses per month
Matches the Vyleesi prescribing information. Doses should be at least 24 hours apart. Self-administered in the abdomen or thigh.
Protocol 2
Entry Research Protocol
Dose
0.5-1mg subcutaneous, 45-60 minutes pre-activity
Duration
On-demand
Lower-end exploratory dose used to assess tolerability before stepping to the labeled 1.75mg. Nausea is the most common dose-limiting effect in RECONNECT.
Protocol 3
Standard Research Variant
Dose
1mg-1.75mg subcutaneous as needed
Duration
On-demand, spaced ≥24h apart
Matches the published clinical effective range. Onset typically 30-60 minutes; effect window 6-12 hours.
Protocol 4
Nasal Research Variant (research-only)
Dose
1mg-2mg intranasal, single use
Duration
On-demand
Nasal route is RESEARCH-ONLY and is NOT an FDA-approved formulation of bremelanotide. Bioavailability differs materially from subcutaneous; published clinical data is limited.
Mixing Math
Reconstitution
Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.
Vial size
10mg vial
BAC water
2ml bacteriostatic water
Concentration
5mg/ml
Dose / ml
1.75mg = 0.35ml · 1mg = 0.2ml
Syringe units
35 IU (1.75mg) · 20 IU (1mg) on U-100
Frequently Paired
Common Stacks
Storage
Handling Notes
Lyophilized: 2-8°C preferred, -20°C for extended storage. Reconstituted: refrigerate at 2-8°C and use within 28 days. Protect from light. Bring to room temperature before injection to reduce sting.
Research Considerations
Cautions
- Per Vyleesi label: max 8 doses per month and at least 24 hours between doses. More frequent use was not studied.
- Transient blood pressure rise (mean ~6 mmHg systolic) reported in RECONNECT. Avoid use in uncontrolled hypertension or cardiovascular disease.
- Focal hyperpigmentation can occur with repeated dosing, especially on the face, gums, or breasts. More common with frequent administration and in darker skin types.
- Nausea is the most common adverse effect. Antiemetic premedication is sometimes used in research contexts.
- Nasal formulations are not FDA approved. Use only for research purposes with awareness that pharmacokinetics differ from the SC label.
Ready to start your research
Get PT-141 (Bremelanotide) from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy PT-141 (Bremelanotide) nowResearch use only. Not medical advice. Browse all dosage charts